42 results on '"Mok, T"'
Search Results
2. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology
3. The impact of COVID-19 on cancer care and oncology clinical research: an experts’ perspective
4. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study
5. How to make the best use of immunotherapy as first-line treatment of advanced/metastatic non-small-cell lung cancer
6. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study
7. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial
8. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
9. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer
10. Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus
11. 389P Updated analysis from the KEYNOTE-042 China study: 1L pembrolizumab (pembro) vs chemotherapy (chemo) in Chinese patients (pts) with advanced NSCLC with PD-L1 TPS ≥1%
12. 367P Detection of epidermal growth factor receptor mutations (EGFR-mut) from cell-free DNA in pleural effusion (PE-DNA) of patients with non-small cell lung cancer (NSCLC)
13. LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study
14. 1412TiP Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
15. 1307P Blood-based genomic profiling of advanced non-small cell lung cancer (aNSCLC) patients (pts) from blood first assay screening trial (BFAST) and comparison with real-world data (RWD)
16. 1301P Blood first assay screening trial (BFAST) in patients (pts) with 1L NSCLC: ALK+ cohort updated biomarker analyses
17. 1293P IMpower150: Updated efficacy analysis in patients with EGFR mutations
18. 1265P IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
19. 1781MO IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
20. 492O - Osimertinib for patients (pts) with leptomeningeal metastases (LM) associated with EGFRm advanced NSCLC
21. LBA57 - Overall survival results of ceritinib in ALKi-naïve patients with ALK-rearranged NSCLC (ASCEND-3)
22. 1500TiP - eXalt3: Phase III randomized study comparing ensartinib to crizotinib in anaplastic lymphoma kinase positive non-small cell lung cancer patients
23. 100P - Afatinib vs gefitinib for treatment-naïve patients with EGFRm+ NSCLC (LUX-Lung 7): Analysis of time to treatment failure and impact of afatinib dose adjustment
24. 93PD - Afatinib (A) vs gefitinib (G) in patients with EGFR mutation-positive (EGFRm+) NSCLC: Updated OS data from the phase IIb trial LUX-Lung 7 (LL7)
25. 85O_PR - Patient-reported symptoms and impact of treatment with osimertinib vs chemotherapy for advanced non-small cell lung cancer
26. 2060 - Afatinib vs gefitinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: overall survival (OS) data from LUX-Lung 7 (LL7)
27. 1991 - First-line afatinib for advanced EGFR mutation-positive (EGFRm+) NSCLC: analysis of long-term responders in the Phase III LUX-Lung 3, 6 and 7 trials
28. Corrections to “Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials”
29. 1226PD - Impact of Crizotinib on Patient-Reported Symptoms and Global Quality of Life (Qol) Compared with Platinum Based Chemotherapy in Phase III Study of Treatment Naïve Advanced Alk-Positive Non-Small Cell Lung Cancer (Nsclc)
30. 1251P - Updated Analysis of Response and Patient-Reported Outcomes (Pro) in Two Large Open-Label, Phase III Studies (Lux-Lung 3 [Ll3] and Lux-Lung 6 [Ll6]) of Afatinib (A) Versus Chemotherapy (Ct) in Patients (Pts) with Advanced Nsclc Harboring Egfr Mutations (Mut)
31. 1243P - Dacomitinib (D) Versus Erlotinib (E) in 2Nd/3Rd Line Nsclc: Outcome for Asian Patients from the Archer 1009 Global Phase 3 Trial
32. OP3 Cost-effectiveness of epidermal growth-factor receptor mutation testing and first-line treatment with gefitinib for advanced non-small-cell lung cancer
33. OP78 EGFR mutations based on circulating free DNA (cfDNA) in the subset of Japanese patients (pts) from IPASS (IRESSA Pan ASia Study), a Phase III study of first-line gefitinib (G) vs carboplatin/paclitaxel (C/P) in clinically selected patients with advanced non-small-cell lung cancer (NSCLC)
34. 9154 Clinical outcomes in patients with EGFR mutations: pooled analysis of NSCLC patients treated with either an EGFR TKI or chemotherapy
35. 9007 Randomized, double-blind phase II/III study of first-line paclitaxel (P) plus carboplatin (C) in combination with vorinostat or placebo in patients with advanced non-small-cell lung cancer (NSCLC)
36. 9003 Response and progression-free survival in 1006 patients with known EGFR mutation status in phase III randomized trials of gefitinib in individuals with non-small cell lung cancer
37. 6516 A scoring system in predicting the risk of hepatocellular carcinoma in chronic hepatitis B carrier
38. Being molecular in the molecular age
39. 2LB Phase III, randomized, open-label, parallel-group study of oral gefitinib (IRESSA) versus intravenous docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer who have previously received platinum- based chemotherapy (INTEREST)
40. The effects of progressive muscle relaxation training in the management of chemotherapy-induced nausea and vomiting: a randomised controlled trial
41. Identification of therapeutic targets and medicines for comorbid Crohn's disease and rheumatoid arthritis: A comprehensive analysis.
42. Recurrent respiratory papillomatosis (RRP) of tracheobronchial tree presenting as lung collapse with malignant transformation after a decade.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.